Gilead SciencesGILD

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company built around antiviral therapeutics, with the majority of revenue historically derived from its HIV franchise, anchored by single-tablet regimens such as Biktarvy and the long-acting agents that succeeded the tenofovir-based backbone that once defined the category. A meaningful second pillar comes from liver disease, principally chronic hepatitis B and C and, increasingly, primary biliary cholangitis. Oncology, expanded materially through cell therapy (Yescarta, Tecartus) and antibody-drug conjugates (Trodelvy), forms a third and growing line, alongside a smaller inflammation portfolio. Products are sold directly and through specialty distributors to hospitals, retail and specialty pharmacies, government programs, and managed care. HIV therapies typically drive the bulk of operating profit.

Investors tend to focus on the durability of the HIV franchise given periodic patent step-downs, the pace at which long-acting injectables can defend share against generic and competitor oral regimens, and progress translating the Kite cell-therapy platform and Trodelvy into sustained oncology contribution. Concentration on a handful of high-volume products, exposure to U.S. government pricing mechanisms including 340B, Medicaid rebates, and Inflation Reduction Act negotiation, and payer mix in HIV prevention are structural considerations. Capital allocation — a consistent dividend, opportunistic buybacks, and periodic large bolt-on acquisitions — shapes the balance sheet. Governance is a single-class share structure with an independent chair convention adopted in recent years.

Gilead was founded in 1987 in Foster City, California by Michael Riordan, initially as an oligonucleotide research company, and shifted decisively into small-molecule antivirals through the 1990s under John Martin's leadership. Milestones include the 1999 acquisition of NeXstar (AmBisome), the 2003 Triangle Pharmaceuticals deal that brought emtricitabine, the launch of Truvada and later Atripla, and the transformational 2011 acquisition of Pharmasset, which yielded sofosbuvir and reshaped hepatitis C treatment. The 2017 purchase of Kite Pharma added CAR-T capabilities, and Immunomedics in 2020 brought Trodelvy. The company remains headquartered in Foster City and operates as a single, integrated corporate structure with global subsidiaries.

Revenue flows primarily through wholesalers and specialty distributors that resell to pharmacies, hospitals, and clinics, with meaningful direct interaction on cell therapies, which require certified treatment centers and complex logistics for autologous manufacturing. Contracting is dominated by rebate arrangements with pharmacy benefit managers, managed care organizations, the Department of Veterans Affairs, Medicaid, and mandatory 340B discounts to safety-net providers. Competitive position rests on formulary access, clinical differentiation in tolerability and dosing, and lifecycle management of long-lived franchises. In HIV, GlaxoSmithKline's ViiV Healthcare is the principal rival; in oncology, competition spans Novartis, Bristol-Myers Squibb, and AstraZeneca. The United States generates the substantial majority of sales, with Europe and Japan the main international markets.

Company profile by LineVest editorial. Journalism, not investment advice.